Clinical Trials Logo
  1. Home
  2. Bladder Cancer
  3. NCT03138837
  4. Details
NCT03138837 Clinical Trial

Role of 3 Tesla Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) for Diagnosis Bladder Cancer Grade and Stage

Bladder Cancer Clinical Trial

Official title:
Role of 3 Tesla Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) for Diagnosis Bladder Cancer Grade and Stage. Potential Role of the Apparent Diffusion Coefficient (ADC) Value

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03138837
Other study ID # R/17.02.31
Secondary ID
Status Recruiting
Phase N/A
First received May 1, 2017
Last updated May 16, 2017
Start date May 15, 2017
Est. completion date May 15, 2018

Study information
Verified date May 2017
Source Mansoura University
Contact Abdelwahab R. Hashem, Msc
Phone 01069678979
Email abdelwahab_hashem@yahoo.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

assess diagnostic performance of 3-Tesla DW-MRI in detecting and staging bladder cancer and potential role of the ADC value as a biomarker reflecting histological grade and stage.

Recruitment information / eligibility
Status Recruiting
Enrollment 385
Est. completion date May 15, 2018
Est. primary completion date May 15, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Men and women 18 years or older

- Suspected by the out-patient flexible cystoscopy as Non-muscle invasive bladder cancer.

- Patient who will undergo radical cystectomy.

- Patient with history of allergy to iodinated contrast media

Exclusion Criteria:

- Refuse to complete study requirements

- Patient with any of the following:

1. Any metallic fragment or foreign body

2. Coronary and peripheral artery stents

3. Aortic stent graft

4. Prosthetic heart valves and annuloplasty rings

5. Cardiac pacemaker

6. Implanted cardioverter-defibrillator (ICD)

7. Retained trans venous pacemaker and defibrillator leads

8. Cochlear, otologic, or other ear implant

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Magnetic resonance imaging
Diffusion Weighted Magnetic resonance imaging

Locations
Country Name City State
Egypt Urology and Nephrology Center Mansoura Aldakahlia

Sponsors (1)
Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary assess the diagnostic performance of 3-T DW-MRI in detecting and staging bladder cancer comparing the radiological diagnosis with the pathological specimen results 1 year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A